Potential Association Between Changes in Microbiota Level and Lung Diseases: A Meta-Analysis

• Published in: Frontiers in medicine 2022-01, Vol.8, p.723635-723635
• Main Authors: Chai, Lan, Wang, Qi, Si, Caijuan, Gao, Wenyan, Zhang, Lun
• Format: Article
• Language: English
• Subjects: asthma; COPD; IPF—idiopathic pulmonary fibrosis; lung microbiota; Medicine; meta-analysis
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2021.723635

Lung microbiota is increasingly implicated in multiple types of respiratory diseases. However, no study has drawn a consistent conclusion regarding the relationship between changes in the microbial community and lung diseases. This study verifies the association between microbiota level and lung diseases by performing a meta-analysis. Literature databases, including PubMed, ISI Web of Science, Embase, Google Scholar, PMC, and CNKI, were used to collect related articles published before March 20, 2021. The standard mean deviation (SMD) and related 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup, sensitivity, and publication bias analyses were also conducted. Six studies, comprising 695 patients with lung diseases and 176 healthy individuals, were included in this meta-analysis. The results indicated that the microbiota level was higher in patients with lung diseases than in healthy individuals (SMD = 0.39, 95% CI = 0.22-0.55, = 91.5%, < 0.01). Subgroup analysis based on country demonstrated that the microbiota level was significantly higher in Chinese (SMD = 1.90, 95% CI = 0.87-2.93, = 62.3%, < 0.01) and Korean (SMD = 0.24, 95% CI = 0.13-0.35, = 78.7%, < 0.01) patients with lung diseases. The microbiota level of patients with idiopathic pulmonary fibrosis (IPF) (SMD = 1.40, 95% CI = 0.42-2.38, = 97.3%, = 0.005), chronic obstructive pulmonary disease (COPD) (SMD = 0.30, 95% CI = 0.09-0.50, = 83.9%, = 0.004), and asthma (SMD = 0.19, 95% CI = 0.06-0.32, = 69.4%, = 0.004) were significantly higher than those of the healthy group, whereas a lower microbiota level was found in patients with chronic hypersensitivity pneumonitis (CHP). The microbiota level significantly increased when the disease sample size was >50. Subgroup analysis based on different microbiota genera, indicated that and were significantly increased in COPD and asthma diseases. We observed that patients with IPF, COPD, and asthma had a higher microbiota level, whereas patients with CHP had a lower microbiota level compared to the healthy individuals. The level of and were significantly higher in patients with COPD and asthma, and thus represented as potential microbiota markers in the diagnosis and treatment of lung diseases.